Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Prasugrel Achieves Primary Endpoint in Domestic PIII Trial, Expects to Submit NDA in FY2013: Daiichi Sankyo
September 24, 2012
- Novartis to File for Additional Indication for Lucentis in Japan within This Year
September 24, 2012
- Pfizer Preparing for Assault on Domestic Generic Drug Market with Help from Mylan
September 24, 2012
- MTPC Launches Simponi in Indonesia
September 21, 2012
- Nichi-Iko to Set Up New Sections in Sales, Development Divisions to Enhance Oncology Field
September 21, 2012
- Nippon Shinyaku Files for Additional Indication of Chronic Pain for Tramal Capsule
September 21, 2012
- Chugai Applies for Avastin for Recurrent Glioblastoma
September 21, 2012
- Astellas, KEK Announce Collaboration to Develop New Drugs for NTDs
September 21, 2012
- Intellim Establishes Local Office in South Korea, Set to Realize Asian Studies
September 20, 2012
- TS-1 Shows Non-Inferiority to Gemcitabine in Effect on Resected Pancreatic Cancer: Taiho
September 20, 2012
- Symptoms of Cedar Pollen Allergy Reduced in PIII Trial for Sublingual Immunotherapy Drug: Torii
September 20, 2012
- Kitasato Daiichi Sankyo Vaccine to Discontinue Animal Vaccine, to Focus on Human Vaccines
September 20, 2012
- Maruho to Acquire Shares of Maeda Pharmaceutical through Third-Party Allocation
September 20, 2012
- 72% of GPs, 41% of Hospital Doctors Issue Generic Name Prescriptions After April: Sawai Survey
September 20, 2012
- DSP Launches Latuda in Canada
September 19, 2012
- Eli Lilly Japan Applies for Strattera Oral Solution
September 19, 2012
- 60% of Sales to Come from Specialty Field, Oncology by 2017: President Mitani of Novartis Pharma
September 19, 2012
- Janssen Pharmaceutical Discontinues PII Study for Atopic Dermatitis Treatment in Japan
September 19, 2012
- Eisai to Push Efficacy of Careram in Combination with MTX, Low Drug Costs
September 19, 2012
- MTPC, Daiichi Sankyo Conduct Largest Ever Copromotion for Tenelia, Aiming for Top Position in Diabetes Market with SGLT-2 Inhibitor
September 19, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…